{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:32:31Z","timestamp":1791297151411,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81600482"],"award-info":[{"award-number":["No. 81600482"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["No. 2020CFB600, No. 2019CFB501"],"award-info":[{"award-number":["No. 2020CFB600, No. 2019CFB501"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["No. 2018M632875, No. 2019T120671"],"award-info":[{"award-number":["No. 2018M632875, No. 2019T120671"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer, a major cause of cancer-related mortality in women, remains challenging to treat, particularly in recurrent or metastatic stages. Immunotherapy offers promise, but reliable biomarkers for predicting outcomes are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A cohort of 204 patients with recurrent or metastatic cervical cancer who underwent immunotherapy was included in the study. Predictive factors were identified using LASSO regression combined with multivariate Cox proportional hazards analysis. Nomograms for progression-free survival (PFS) and overall survival (OS) were constructed by incorporating significant prognostic variables. Internal validation was performed via bootstrap resampling, and clinical applicability was assessed through decision curve analysis (DCA). Risk stratification was evaluated using Kaplan-Meier survival curves, with log-rank tests for comparison. In addition, to enhance the clinical applicability of the model, we downloaded external multi-center validation datasets from public databases, including TCGA (The Cancer Genome Atlas) and GEO (Gene Expression Omnibus). Data from 306 cervical cancer patients were obtained and used as an independent validation cohort. These external datasets allowed for the verification of the developed model, ensuring its robustness and generalizability across different clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis identified several significant prognostic factors for PFS, including histological type, maximum lesion diameter, CA125 levels, albumin concentration, lactate dehydrogenase (LDH) activity, and neutrophil-to-lymphocyte ratio (NLR). For OS, independent factors included BMI, liver metastasis, CEA levels, hemoglobin concentration, albumin levels, and LDH. The nomogram models demonstrated strong predictive accuracy, with concordance indices (C-index) of 0.706 for PFS and 0.769 for OS. Calibration curves indicated that the predicted and actual outcomes were in excellent agreement. The area under the curve (AUC) values for PFS at 1- and 2-year follow-up were 0.804 and 0.822, respectively, while for OS, the AUC values were 0.880 and 0.781. The risk stratification based on the nomogram scores revealed significant survival differences between high- and low-risk patients, with the high-risk group exhibiting poorer survival outcomes. External validation using data from the TCGA and GEO cohorts confirmed the robustness and generalizability of the nomogram models, further supporting their clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These nomograms provide a reliable tool for predicting outcomes in cervical cancer immunotherapy, helping to personalize treatment and improve clinical management, especially for metastatic disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1662605","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:11Z","timestamp":1765175351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and validation of immunotherapy nomogram for predicting the efficacy and prognosis of recurrent and metastatic cervical cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhongan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e49968","DOI":"10.2196\/49968","article-title":"Nasopharyngeal cancer incidence and mortality in 185 countries in 2020 and the projected burden in 2040: population-based global epidemiological profiling","volume":"9","author":"Zhang","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN guidelines\u00ae Insights: cervical cancer, version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6102","article-title":"Increased expression of PD\u2212L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.07.003","article-title":"The role of biomarkers for the prediction of response to checkpoint immunotherapy and the rationale for the use of checkpoint immunotherapy in cervical cancer","volume":"31","author":"Otter","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae009","article-title":"Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial","volume":"116","author":"Othus","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1115706","article-title":"Alkaline phosphatase combined with \u03b3-glutamyl transferase is an independent predictor of prognosis of hepatocellular carcinoma patients receiving programmed death-1 inhibitors","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02337-3","article-title":"Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy","volume":"22","author":"Banna","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005977","article-title":"New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors","volume":"11","author":"Bamias","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.027","article-title":"Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)","volume":"84","author":"Bigot","year":"2017","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100578","DOI":"10.1016\/j.ctro.2023.100578","article-title":"Circulating neutrophils and tumor-associated myeloid cells function as a powerful biomarker for response to chemoradiation in locally advanced cervical cancer","volume":"39","author":"Gjyshi","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","article-title":"Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab","volume":"6","author":"Capone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","article-title":"Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies","volume":"18","author":"Cupp","year":"2020","journal-title":"BMC Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01055","article-title":"Changes in nutritional status impact immune cell metabolism and function","volume":"9","author":"Alwarawrah","year":"2018","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.03.001","article-title":"Connecting the metabolic and immune responses to cancer","volume":"23","author":"Flint","year":"2017","journal-title":"Trends Mol Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41698-022-00267-7","article-title":"Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade","volume":"6","author":"Yoo","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.12.010","article-title":"Serum albumin: early prognostic marker of benefit for immune checkpoint inhibitor monotherapy but not chemoimmunotherapy","volume":"23","author":"Guo","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1920413117","article-title":"Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity","volume":"117","author":"Hermans","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.11.032","article-title":"Rationale for LDH-targeted cancer immunotherapy","volume":"181","author":"Miholjcic","year":"2023","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1717185","article-title":"Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task","volume":"16","author":"Ni","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_414_17","article-title":"Serum expression level of squamous cell carcinoma antigen, highly sensitive C-reactive protein, and CA-125 as potential biomarkers for recurrence of cervical cancer","volume":"13","author":"Guo","year":"2017","journal-title":"J Cancer Res Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00780-3","article-title":"Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma","volume":"34","author":"Huang","year":"2021","journal-title":"Mod Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.547333","article-title":"The immune heterogeneity between pulmonary adenocarcinoma and squamous cell carcinoma: A comprehensive analysis based on lncRNA model","volume":"12","author":"Yan","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2661","article-title":"Obesity is associated with altered tumor metabolism in metastatic melanoma","volume":"29","author":"Hahn","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1038\/s41598-019-39150-0","article-title":"Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer","volume":"9","author":"Huang","year":"2019","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:29:12Z","timestamp":1765175352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2025.1662605"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1662605","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1662605"}}